Skip to main
SGHT
SGHT logo

Sight Sciences (SGHT) Stock Forecast & Price Target

Sight Sciences (SGHT) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 50%
Buy 0%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Sight Sciences Inc's positive outlook is supported by potential drivers for revenue growth, including faster-than-anticipated market share gains in the minimally invasive glaucoma surgery (MIGS) segment and accelerated adoption of its TearCare system. The company is positioned to sustain growth in its Surgical Glaucoma segment, which aligns with the overall MIGS market trends. Additionally, revised earnings per share (EPS) projections for 2025 and 2026 reflect a decrease in losses, indicating an improving financial trajectory as the company aims towards profitability.

Bears say

Sight Sciences Inc. has reiterated its revenue guidance for 2025 in the range of $72-76 million, while simultaneously forecasting a mid-single-digit percentage decline in Surgical Glaucoma revenue for the third quarter of 2025, indicating challenges in its primary revenue-generating segment. Additionally, the company faces significant risks including heightened competition in the minimally invasive glaucoma surgical (MIGS) market, slow advancement towards securing insurance coverage for its TearCare product, and persistent quarterly cash burn issues. Although management has adjusted its operating expense guidance downward, anticipating annualized savings of $12 million, the overall financial outlook remains pressured by these obstacles and declining revenue expectations.

Sight Sciences (SGHT) has been analyzed by 6 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Sight Sciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Sight Sciences (SGHT) Forecast

Analysts have given Sight Sciences (SGHT) a Buy based on their latest research and market trends.

According to 6 analysts, Sight Sciences (SGHT) has a Buy consensus rating as of Nov 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Sight Sciences (SGHT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.